MB-07133
MB-07133 is in phase III clinical trials for the treatment of hepatocellular carcinoma (HCC). In 2007, orphan drug designation was received in the U.S. for the treatment of primary liver cancer.
The compound was originally developed by Metabasis (acquired by Ligand in 2010), licensed to Chiva by Ligand in 2011.
General Information
Update Date：2016-04-05
- Drug Name：
- MB-07133
- Research Code：
- MB-07133; MB-7133
- Trade Name：
- MOA：
- an antimetabolic agent and DNA synthesis inhibitor
- Indication：
- Hepatocellular carcinoma (HCC)
- Status：
- Phase Ⅲ (Active)
- Company：
- Ligand (Originator) , Chiva
- Sales：
- ATC Code：
Chemical Structure
Update Date：2015-10-26
|
Molecular Weight | 440.34 | ||||||||||||
| Formula | C17H21N4O8P | |||||||||||||
| CAS No. | 685111-92-6 (MB 07133); | |||||||||||||
| Chemical Name | 2(1H)-Pyrimidinone, 4-amino-1-[5-O-[(2R,4S)-2-oxido-4-(4-pyridinyl)-1,3,2-dioxaphosphorinan-2-yl]-b-D-arabinofuranosyl]- | |||||||||||||
| MB 07133 （Free Acid/Base）Parameters： | ||||||||||||||
|
||||||||||||||
| *：Calculated by ACD/Labs software V11.02. | ||||||||||||||